DKSH extends partnership with Novo Nordisk in Malaysia

DKSH Business Unit Healthcare, the leading partner for healthcare companies seeking to grow their business in Asia, has signed an agreement to provide marketing, sales and distribution services for Novo Nordisk’s NovoFine® insulin needles in pharmacy channels in Malaysia.

Developed in response to input from patients and healthcare professionals, NovoFine® 31G and 32G insulin needles are designed specifically to simplify the insulin injection process and make injection more comfortable. NovoFine®
needles incorporate Superflow™ technology which makes injection quicker and easier, reducing the effort needed to inject insulin.

“DKSH’s commitment to quality and compliance as well as track record in the healthcare industry has made them our partner of choice. We are confident that this partnership will help strengthen NovoFine® insulin needles position in the pharmacy channels and give patients better access to our diabetic care products,” said Noha Shawky, General  Manager, Novo Nordisk Pharma, Malaysia.

“We are pleased that Novo Nordisk has chosen DKSH to support NovoFine® insulin needles with our extensive commercial capabilities. The agreement reflects our strength, reputation and unrivalled capillary distribution network in the healthcare channels in Malaysia,” commented  Dr. Marc Franck, Vice President Business Unit Healthcare, DKSH Malaysia.

DKSH already provides an integrated Market Expansion Services service portfolio that includes marketing and sales, distribution and logistics, credit management and collection services for Novo Nordisk’s entire product range to the hospital, clinic and pharmacy channels in Malaysia.

The new partnership will further strengthen DKSH’s market position in Malaysia while contributing incrementally to the Group’s overall profitability over time.